CoChat

May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance

Open access
Fava, Giovanni A. · 2020 · Therapeutic Advances in Psychopharmacology

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index; 45 of the 136 sources its claims cite were checked for support.

Abstract

In recent years there has been a considerable debate on antidepressant drugs. Continued drug treatment with antidepressant medications may stimulate processes that run counter to the initial acute effects of a drug. The oppositional model of tolerance may explain loss of treatment efficacy during maintenance treatment and the fact that some side effects tend to occur only after a certain time. These processes may also direct the illness into a treatment-unresponsive course, including manifestations of bipolar disorder or paradoxical reactions. When drug treatment ends, oppositional processes no longer encounter resistance, resulting in potential onset of new withdrawal symptoms, persistent post-withdrawal disorders, hypomania, and resistance to treatment if it is reinstituted. In all these cases, antidepressant medications may constitute a form of iatrogenic comorbidity, which increases chronicity and vulnerability to depressive episodes. Antidepressant medications are essential drugs for the treatment of major depressive episodes. They are less likely, however, to provide protection for relapse prevention. Current prescription practices need to be reformulated in light of consideration of vulnerabilities and adverse effects of treatment. The oppositional model of tolerance provides a conceptual framework for weighing all these elements in the individual case. The model does not appear to apply to all patients who undergo treatment with AD, but only to a part of them. Studying the variables that are associated with such occurrence in certain patients and not in others would be one of the most important tasks of current therapeutic research. Current diagnostic systems in psychiatry do not consider the iatrogenic components of psychopathology, and can be applied to only patients who are drug free. They are suited for a patient who no longer exists: most of the cases that are seen in psychiatric clinical practice receive psychotropic drugs and such treatment is likely to affect prognosis and treatment choices.

Overview

CoChat Summary

TL;DR

Fava reviews clinical evidence for the oppositional model of tolerance, arguing that antidepressant drugs can paradoxically worsen mood and anxiety disorders in some patients through loss of efficacy, resistance, paradoxical reactions, switching, withdrawal, and refractoriness. He concludes antidepressants remain essential for severe depression but that long-term and anxiety-disorder prescribing should be reconsidered; the model applies only to a fraction of patients and still awaits adequate testing.

Key findings

  • The oppositional model posits three phases: early treatment (up to 6 weeks) with paradoxical reactions and hypomania/mania; long-term treatment with paradoxical reactions, hypomania/mania, loss of clinical effects, delayed side effects, and refractoriness; and post-treatment with new withdrawal symptoms, hypomania/mania, persistent post-withdrawal disorder, and resistance if the same treatment is reinstituted.
  • Loss of antidepressant efficacy: in a meta-analysis of maintenance treatment studies, relapse risk increased from 23% within 1 year to 34% in 2 years and 45% in 3 years. In a fluoxetine maintenance study, about one-third relapsed within an average of 107 days; dose increase produced response in 57% of daily-dosage patients and 72% of weekly-dosage patients, and one in five initial dose responders relapsed again during the 25-week trial.
  • Resistance/rechallenge: a systematic review found response failures ranging from 4.9% to 42.9%; a large observational study found failure to respond to the same medication in a quarter of cases; among 122 patients who initially responded to fluoxetine and were assigned to placebo, about half relapsed, and after fluoxetine re-initiation 38% did not respond at all or relapsed after an initial response.
  • STAR*D: first open citalopram treatment yielded 37% remission and 15% who responded and stayed well for a year; cumulative remission after four sequential steps was 67%, but persistent recovery was 43%, with step one yielding only an additional 6% of sustained recovery; remission decreased after each step while relapse on medication and intolerance increased. A juvenile meta-analysis found excessive arousal-activation with antidepressants in anxiety (13.8%) and depression (9.8%) versus placebo (5.2% and 1.1%, respectively).

Methods

  • Narrative/conceptual review by the originator of the oppositional model; the paper states it does not aim to be exhaustive and cites only illustrative investigations to outline clinical insights.
  • Synthesizes clinical phenomena reported during or after antidepressant treatment: loss of antidepressant efficacy, resistance, paradoxical effects, switching to bipolar course, withdrawal reactions, and refractoriness.
  • Draws on selected trials and meta-analyses (e.g., maintenance relapse meta-analysis, fluoxetine/duloxetine relapse studies, STAR*D, juvenile activation meta-analysis) to support the model; no new primary data are presented.

Limitations

  • The paper states the model was “largely speculative” at its formulation and still awaits adequate preclinical and clinical research testing; it does not appear to apply to all patients treated with antidepressants, but only to a fraction, and the variables associated with occurrence in some patients remain to be studied.
  • The paper states the review is not exhaustive and only illustrative investigations are cited.
  • Evident from the text: this is a narrative review with selective citation by a proponent/originator of the model, without a systematic search or formal risk-of-bias assessment; many cited findings are from other studies and are not re-analyzed here.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/2045125320970325

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

13 Valid · 2 Not valid · 67 Not checked · 34 Own results and interpretations

73 more claims · 3 with their cited sources checked

Create a free account to see all 116 claims and to verify the 91 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 83 references

Research works printed but not linked: 1

  1. Goodwin FK The biology of recurrence: new directions for the pharmacological bridge. J Clin Psychiatry 1989; 50(Suppl. 40–44): discussion 45– 47. 2689436

Cited by

See all 84

Metadata

Authors
Fava, G. A.
Affiliations
Erie County Medical Center (US)
Corresponding author
Fava, Giovanni A.
Venue
Therapeutic Advances in Psychopharmacology
Published
2020-01
Volume
10
Pages
2045125320970325-2045125320970325
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W3097539185
Cited by
84
References
83
Citations by year
2026: 9 · 2025: 18 · 2024: 18 · 2023: 15 · 2022: 12 · 2021: 10
FWCI
1.21
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
antidepressants, antidepressant side effects, paradoxical reaction, bipolar disorder, treatment-resistant depression, antidepressant withdrawal symptoms, hypomania, relapse prevention, major depressive episode, chronicity of depression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. https://app.cochat.ai/papers/10.1177/2045125320970325
The paper
Fava, G. A. (2020). May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320970325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.